Search Results - "Van Krieken, Johan H. J. M."

Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme by Dequeker, Elisabeth, Ligtenberg, Marjolijn J. L., Vander Borght, Sara, van Krieken, Johan H. J. M.

“…In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS ( KRAS ) wild-type colorectal tumors. Information on the KRAS status of the…”
Get full text

Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization by Schraders, Margit, Pfundt, Rolph, Straatman, Huub M.P., Janssen, Irene M., van Kessel, Ad Geurts, Schoenmakers, Eric F.P.M., van Krieken, Johan H.J.M., Groenen, Patricia J.T.A.

“…Mantle cell lymphoma (MCL) is an aggressive, highly proliferative B-cell non-Hodgkin lymphoma, characterized by the specific t(11;14)(q13;q32) translocation…”
Get full text

Lymph Node Retrieval in Rectal Cancer is Dependent on Many Factors-the Role of the Tumor, the Patient, the Surgeon, the Radiotherapist, and the Pathologist by MEKENKAMP, Leonie J. M, VAN KRIEKEN, Johan H. J. M, MARIJNEN, Corrie A. M, VAN DE VELDE, Cornelis J. H, NAGTEGAAL, Iris D

“…Lymph node status is the strongest prognostic factor for survival in colorectal cancer. There are several guidelines concerning the minimum numbers of lymph…”
Get full text

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer by Pander, Jan, Gelderblom, Hans, Antonini, Ninja F, Tol, Jolien, Krieken, Johan H.J.M. van, Straaten, Tahar van der, Punt, Cornelis J.A, Guchelaar, Henk-Jan

“…Abstract Background Next to KRAS mutation status, additional predictive markers are needed for the response to cetuximab in patients with metastatic colorectal…”
Get full text

Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase by Groenen, Patricia J T A, Blokx, Willeke A M, Diepenbroek, Coos, Burgers, Lambert, Visinoni, Franco, Wesseling, Pieter, van Krieken, Johan H J M

“…Groenen P J T A, Blokx W A M, Diepenbroek C, Burgers L, Visinoni F, Wesseling P & van Krieken J H J M
(2011) Histopathology59, 1–7 Preparing pathology for…”
Get full text

Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas by Muris, Jettie J.F., Cillessen, Saskia A.G.M., Vos, Wim, van Houdt, Inge S., Kummer, J.Alain, van Krieken, Johan H.J.M., Jiwa, N.Mehdi, Jansen, Patty M., Kluin-Nelemans, Hanneke C., Ossenkoppele, Gert J., Gundy, Chad, Meijer, Chris J.L.M., Oudejans, Joost J.

“…We used biopsy specimens of primary nodal diffuse large B-cell lymphoma (DLBCL) to investigate whether the inhibition of caspase 8 and/or 9 apoptosis signaling…”
Get full text

Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene‐dosage regulated candidate genes by Schraders, Margit, Jares, Pedro, Bea, Silvia, Schoenmakers, Eric F. P. M., Van Krieken, Johan H. J. M., Campo, Elias, Groenen, Patricia J. T. A.

“…Summary Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation and several other cytogenetic aberrations, including heterozygous…”
Get full text

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer by Tol, Jolien, Koopman, Miriam, Cats, Annemieke, Rodenburg, Cees J, Creemers, Geert J.M, Schrama, Jolanda G, Erdkamp, Frans L.G, Vos, Allert H, van Groeningen, Cees J, Sinnige, Harm A.M, Richel, Dirk J, Voest, Emile E, Dijkstra, Jeroen R, Vink-Börger, Marianne E, Antonini, Ninja F, Mol, Linda, van Krieken, Johan H.J.M, Dalesio, Otilia, Punt, Cornelis J.A

“…Capecitabine, oxaliplatin, and bevacizumab are standard treatment for metastatic colorectal cancer. This trial tested whether adding cetuximab to this…”
Get full text

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice by Lesterhuis, W Joost, Punt, Cornelis J A, Hato, Stanleyson V, Eleveld-Trancikova, Dagmar, Jansen, Bastiaan J H, Nierkens, Stefan, Schreibelt, Gerty, de Boer, Annemiek, Van Herpen, Carla M L, Kaanders, Johannes H, van Krieken, Johan H J M, Adema, Gosse J, Figdor, Carl G, de Vries, I Jolanda M

“…Tumor microenvironments feature immune inhibitory mechanisms that prevent T cells from generating effective antitumor immune responses. Therapeutic…”
Get full text

Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle cell lymphomas by Ripperger, Tim, von Neuhoff, Nils, Kamphues, Kathrin, Emura, Makito, Lehmann, Ulrich, Tauscher, Marcel, Schraders, Margit, Groenen, Patricia, Skawran, Britta, Rudolph, Cornelia, Callet-Bauchu, Evelyne, van Krieken, Johan H.J.M, Schlegelberger, Brigitte, Steinemann, Doris

“…Institute of Cell and Molecular Pathology (TR, NVN, KK, ME, MT, BS, CR, BS, DS); Institute of Pathology, Hannover Medical School, Germany (UL); Department of…”
Get full text

Prognostic Significance of Metallothionein in Human Gastrointestinal Cancer by JANSSEN, A. Miranda L, VAN DUIJN, Wim, KUBBEN, Frank J. G. M, GRIFFIOEN, Gerrit, LAMERS, Cornelis B. H. W, VAN KRIEKEN, Johan H. J. M, VAN DE VELDE, Cornelis J. H, VERSPAGET, Hein W

“…Purpose: Metallothionein (MT) is a small protein with a high affinity for divalent heavy metal ions. This metalloproteinis involved in many…”
Get full text

Protein profiling in pathology: Analysis and evaluation of 239 frozen tissue biopsies for diagnosis of B-cell lymphomas by Jansen, Corine, Feuth, Ton, Raemaekers, John M. M., Rijntjes, Jos, Meijer, Jos W., Westenend, Pieter J., van Baarlen, Joop, van Krieken, Johan H. J. M., Hebeda, Konnie M., Groenen, Patricia J. T. A.

“…Purpose: We determined the potential value of protein profiling of tissue samples by assessing how precise this approach enables discrimination of B‐cell…”
Get full text

Protein profiling of B-cell lymphomas using tissue biopsies: A potential tool for small samples in pathology by Jansen, Corine, Hebeda, Konnie M, Linkels, Marianne, Grefte, Johanna M M, Raemaekers, John M M, van Krieken, Johan H J M, Groenen, Patricia J T A

“…Non-Hodgkin's lymphoma comprises many related but distinct diseases and diagnosis and classification is complex. Protein profiling of lymphoma biopsies may be…”
Get full text

Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment by Glas, Annuska M., Kersten, Marie José, Delahaye, Leonie J.M.J., Witteveen, Anke T., Kibbelaar, Robby E., Velds, Arno, Wessels, Lodewyk F.A., Joosten, Peter, Kerkhoven, Ron M., Bernards, René, van Krieken, Johan H.J.M., Kluin, Philip M., van't Veer, Laura J., de Jong, Daphne

“…Follicular lymphoma (FL) is a disease characterized by a long clinical course marked by frequent relapses that vary in clinical aggressiveness over time…”
Get full text

High sensitivity of both sequencing and real‐time PCR analysis of KRAS mutations in colorectal cancer tissue by Tol, Jolien, Dijkstra, Jeroen R., Vink‐Börger, Marianne E., Nagtegaal, Iris D., Punt, Cornelis J.A., Van Krieken, Johan H.J.M., Ligtenberg, Marjolijn J.L.

“…The KRAS mutation status predicts the outcome of treatment with epidermal growth factor receptor targeted agents, and therefore the testing for KRAS mutations…”
Get full text

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity by Hato, Stanleyson V, Figdor, Carl G, Takahashi, Susumu, Pen, Anja E, Halilovic, Altuna, Bol, Kalijn F, Vasaturo, Angela, Inoue, Yukie, de Haas, Nienke, Verweij, Dagmar, Van Herpen, Carla M L, Kaanders, Johannes H, van Krieken, Johan H J M, Van Laarhoven, Hanneke W M, Hooijer, Gerrit K J, Punt, Cornelis J A, Asai, Akira, de Vries, I Jolanda M, Lesterhuis, W Joost

“…Platinum-based chemotherapeutics are amongst the most powerful anti-cancer drugs. Although their exact mechanism of action is not well understood, it is…”
Get full text

Metallothionein in human gastrointestinal cancer by Janssen, A. Miranda L., van Duijn, Wim, Oostendorp-van de Ruit, Marjan M., Kruidenier, Laurens, Bosman, Coen B., Griffioen, Gerrit, Lamers, Cornelis B. H. W., van Krieken, Johan H. J. M., van de Velde, Cornelis J. H., Verspaget, Hein W.

“…Metallothionein (MT) is a small thiol‐rich metalloprotein with antioxidant properties, involved in tumour pathophysiology and therapy resistance. In order to…”
Get full text

Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics by Stienen, Jozette J C, Hermens, Rosella P M G, Wennekes, Lianne, van de Schans, Saskia A M, van der Maazen, Richard W M, Dekker, Helena M, Liefers, Janine, van Krieken, Johan H J M, Blijlevens, Nicole M A, Ottevanger, Petronella B

“…The objective of this observational study was to assess the influence of patient, tumor, professional and hospital related characteristics on hospital…”
Get full text

Application of Microfluidic Technology to the BIOMED-2 Protocol for Detection of B-Cell Clonality by Zamò, Alberto, Bertolaso, Anna, van Raaij, Annemiek W.M, Mancini, Francesca, Scardoni, Maria, Montresor, Marina, Menestrina, Fabio, van Krieken, Johan H.J.M, Chilosi, Marco, Groenen, Patricia J.T.A, Scarpa, Aldo

“…The BIOMED-2 protocol is widely used for detecting clonality in lymphoproliferative disorders. The protocol requires multiple PCR reactions, which are analyzed…”
Get full text

Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity by Schraders, Margit, Oeschger, Sabine, Kluin, Philip M, Hebeda, Konnie, Schuuring, Ed, Groenen, Patricia J T A, Hansmann, Martin-Leo, van Krieken, Johan H J M

“…Mantle cell lymphoma is a prime example of a well-defined entity based on morphology, phenotype, genetics and also clinical features. Although most patients…”
Get full text